Logo image of FHTX

FOGHORN THERAPEUTICS INC (FHTX) Stock Fundamental Analysis

USA - NASDAQ:FHTX - US3441741077 - Common Stock

4.46 USD
-0.04 (-0.89%)
Last: 10/9/2025, 10:24:28 AM
Fundamental Rating

2

FHTX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 536 industry peers in the Biotechnology industry. Both the profitability and financial health of FHTX have multiple concerns. While showing a medium growth rate, FHTX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year FHTX has reported negative net income.
FHTX had a negative operating cash flow in the past year.
FHTX had negative earnings in each of the past 5 years.
FHTX had negative operating cash flow in 4 of the past 5 years.
FHTX Yearly Net Income VS EBIT VS OCF VS FCFFHTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

The Return On Assets of FHTX (-33.33%) is better than 63.62% of its industry peers.
Industry RankSector Rank
ROA -33.33%
ROE N/A
ROIC N/A
ROA(3y)-30.61%
ROA(5y)-27.65%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FHTX Yearly ROA, ROE, ROICFHTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K -100K

1.3 Margins

FHTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FHTX Yearly Profit, Operating, Gross MarginsFHTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

More info and screens

3

2. Health

2.1 Basic Checks

FHTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
FHTX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, FHTX has more shares outstanding
There is no outstanding debt for FHTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
FHTX Yearly Shares OutstandingFHTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
FHTX Yearly Total Debt VS Total AssetsFHTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

FHTX has an Altman-Z score of -3.74. This is a bad value and indicates that FHTX is not financially healthy and even has some risk of bankruptcy.
FHTX has a Altman-Z score (-3.74) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.74
ROIC/WACCN/A
WACC9.55%
FHTX Yearly LT Debt VS Equity VS FCFFHTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

FHTX has a Current Ratio of 2.62. This indicates that FHTX is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.62, FHTX is not doing good in the industry: 68.28% of the companies in the same industry are doing better.
A Quick Ratio of 2.62 indicates that FHTX has no problem at all paying its short term obligations.
FHTX has a worse Quick ratio (2.62) than 66.42% of its industry peers.
Industry RankSector Rank
Current Ratio 2.62
Quick Ratio 2.62
FHTX Yearly Current Assets VS Current LiabilitesFHTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

FHTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 38.97%, which is quite impressive.
Looking at the last year, FHTX shows a very negative growth in Revenue. The Revenue has decreased by -31.30% in the last year.
FHTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 157.75% yearly.
EPS 1Y (TTM)38.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.78%
Revenue 1Y (TTM)-31.3%
Revenue growth 3Y157.75%
Revenue growth 5YN/A
Sales Q2Q%9.71%

3.2 Future

Based on estimates for the next years, FHTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.00% on average per year.
Based on estimates for the next years, FHTX will show a very strong growth in Revenue. The Revenue will grow by 22.89% on average per year.
EPS Next Y26.44%
EPS Next 2Y14.35%
EPS Next 3Y8.21%
EPS Next 5Y13%
Revenue Next Year3.71%
Revenue Next 2Y2.49%
Revenue Next 3Y12.77%
Revenue Next 5Y22.89%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
FHTX Yearly Revenue VS EstimatesFHTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
FHTX Yearly EPS VS EstimatesFHTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FHTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FHTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FHTX Price Earnings VS Forward Price EarningsFHTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FHTX Per share dataFHTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.35%
EPS Next 3Y8.21%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FHTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FOGHORN THERAPEUTICS INC

NASDAQ:FHTX (10/9/2025, 10:24:28 AM)

4.46

-0.04 (-0.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)11-03 2025-11-03/bmo
Inst Owners72.73%
Inst Owner Change0%
Ins Owners7.96%
Ins Owner Change0%
Market Cap252.12M
Analysts84.62
Price Target11.9 (166.82%)
Short Float %1.95%
Short Ratio8.85
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.74%
Min EPS beat(2)14.04%
Max EPS beat(2)23.44%
EPS beat(4)4
Avg EPS beat(4)19.64%
Min EPS beat(4)10.09%
Max EPS beat(4)30.99%
EPS beat(8)8
Avg EPS beat(8)25.28%
EPS beat(12)11
Avg EPS beat(12)16.89%
EPS beat(16)11
Avg EPS beat(16)7.4%
Revenue beat(2)2
Avg Revenue beat(2)7.18%
Min Revenue beat(2)0.34%
Max Revenue beat(2)14.02%
Revenue beat(4)3
Avg Revenue beat(4)-6.68%
Min Revenue beat(4)-61.83%
Max Revenue beat(4)20.77%
Revenue beat(8)6
Avg Revenue beat(8)32.27%
Revenue beat(12)7
Avg Revenue beat(12)14.01%
Revenue beat(16)8
Avg Revenue beat(16)19.76%
PT rev (1m)0%
PT rev (3m)10.36%
EPS NQ rev (1m)0.14%
EPS NQ rev (3m)11.07%
EPS NY rev (1m)-0.85%
EPS NY rev (3m)16.39%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-12.25%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.43
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.19
EYN/A
EPS(NY)-1.14
Fwd EYN/A
FCF(TTM)-1.62
FCFYN/A
OCF(TTM)-1.6
OCFYN/A
SpS0.43
BVpS-1.36
TBVpS-1.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.33%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.61%
ROA(5y)-27.65%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.42%
Cap/Sales 3.47%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.62
Quick Ratio 2.62
Altman-Z -3.74
F-Score1
WACC9.55%
ROIC/WACCN/A
Cap/Depr(3y)33.62%
Cap/Depr(5y)290.03%
Cap/Sales(3y)4.61%
Cap/Sales(5y)806.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.78%
EPS Next Y26.44%
EPS Next 2Y14.35%
EPS Next 3Y8.21%
EPS Next 5Y13%
Revenue 1Y (TTM)-31.3%
Revenue growth 3Y157.75%
Revenue growth 5YN/A
Sales Q2Q%9.71%
Revenue Next Year3.71%
Revenue Next 2Y2.49%
Revenue Next 3Y12.77%
Revenue Next 5Y22.89%
EBIT growth 1Y3.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.02%
EBIT Next 3Y8.3%
EBIT Next 5YN/A
FCF growth 1Y19.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.42%
OCF growth 3YN/A
OCF growth 5YN/A